Prevalence of asymptomatic brain metastases in metastatic nonsquamous nonsmall cell lung cancer: Treatment implications for resource-constrained settings
Indian Journal of Cancer · 2024
DOI: 10.4103/ijc.ijc_878_20 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Cancer, 2024. Verfasst von Shubham Shukla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
Brain metastases (BM) are common in metastatic nonsmall cell lung cancer (NSCLC). However, routine neuroimaging in asymptomatic patients with metastatic NSCLC is controversial as there is no conclusive evidence of benefit from the detection and treatment of asymptomatic BM. Herein, we evaluated the prevalence of asymptomatic BM and its treatment implications in a resource-limited setting.
Methods
Consecutive patients with newly diagnosed, treatment-naïve, metastatic, nonsquamous NSCLC (NS-NSCLC) were included. Subjects who already had clinical or radiological features suggestive of BM were excluded from the study. All eligible subjects underwent contrast-enhanced magnetic resonance imaging (MRI) of the brain. Management of the detected BM was at the discretion of the treating clinicians.
Results
Among 809 subjects who were screened, 100 (12.4%) were included in the study and underwent MRI. BM was present in 30 (30%) of the subjects and absent in the remaining 70 subjects. A majority of BM were multiple (70%), involved the frontal lobe commonly (73.3%), and had a mean (standard deviation) size of 13.2 (7.3) mm. Detection of BM resulted in a treatment alteration in 17 (17%) of the study subjects (brain irradiation, n = 17, change in targeted therapy, n = 3) with BM. There was no difference in survival of patients who underwent treatment alteration for management of BM compared to those who did not ( P = 0.132).
Conclusions
About one-third of patients with metastatic NS-NSCLC had BM in MRI despite the absence of symptoms. Despite treatment of the majority of the patients with BM with brain irradiation, there was no demonstrable survival benefit. Hence, we conclude that although routine neuroimaging of asymptomatic patients with newly diagnosed metastatic NSCLC may result in treatment alteration (primarily brain irradiation) in a small proportion of patients, it may not influence outcomes in resource-constrained settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
ORCID-Profile: Shubham Shukla, Kuruswamy Thurai Prasad, Chirag Kamal Ahuja, Valliappan Muthu, Navneet Singh
Zitieren
APA
Shukla, S., Prasad, K. T., Ahuja, C. K., Muthu, V., & Singh, N. (2024). Prevalence of asymptomatic brain metastases in metastatic nonsquamous nonsmall cell lung cancer: Treatment implications for resource-constrained settings. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_878_20
Vancouver
Shukla S, Prasad KT, Ahuja CK, Muthu V, Singh N. Prevalence of asymptomatic brain metastases in metastatic nonsquamous nonsmall cell lung cancer: Treatment implications for resource-constrained settings. Indian Journal of Cancer. 2024. doi:10.4103/ijc.ijc_878_20
BibTeX
@article{Shukla2024,
author = {Shukla, Shubham and Prasad, Kuruswamy Thurai and Ahuja, Chirag Kamal and Muthu, Valliappan and Singh, Navneet},
title = {Prevalence of asymptomatic brain metastases in metastatic nonsquamous nonsmall cell lung cancer: Treatment implications for resource-constrained settings},
journal = {Indian Journal of Cancer},
year = {2024},
doi = {10.4103/ijc.ijc_878_20}
}
EUVIMED